FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients

FDA Approves Tregzi for Chronic GVHD Prevention in Blood Cancer Patients

The U.S. Food and Drug Administration (FDA) has approved Tregzi, a novel allogeneic T-cell-based immunotherapy, for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Tregzi is the first regulatory T (Treg) cell-based immunotherapy approved for this indication. The approval is based on the PRECISION-T clinical trial, where 78% of Tregzi-treated patients achieved chronic GVHD-free survival at one year, significantly higher than the 38.4% in the standard transplant arm. This treatment addresses a critical unmet need by reducing the risk of chronic GVHD, a serious complication that can occur when donor cells attack the patient's body after transplantation.

• Tregzi represents a significant advancement as the first regulatory T (Treg) cell-based immunotherapy approved for preventing chronic graft-versus-host disease (GVHD) in adult blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This donor-derived cellular immunotherapy utilizes purified hematopoietic stem and progenitor cells (HSPCs), Treg cells, and conventional T (Tcon) cells from an HLA-matched donor to regulate immune responses and maintain immune tolerance, thereby reducing GVHD risk while reconstituting the immune system.
• The safety and effectiveness of Tregzi were established in the randomized PRECISION-T clinical trial involving 187 adult patients with blood cancers like acute leukemia and myelodysplastic syndrome. Patients were assigned to receive either Tregzi or a standard stem cell transplant. The primary endpoint was chronic GVHD-free survival, defined as the time from HSCT to the earliest occurrence of death or the first onset of moderate or severe cGVHD within two years after day 0, providing a comprehensive measure of treatment success.
• Results from the PRECISION-T trial demonstrated highly persuasive clinical benefit. At one year, 78% of patients treated with Tregzi achieved chronic GVHD-free survival, a substantial improvement compared to 38.4% of patients who received a standard transplant. Furthermore, Tregzi significantly reduced the incidence of serious chronic GVHD, with only 12.6% of patients developing the condition within one year, versus 44% in the standard transplant group, highlighting its effectiveness in preventing this severe complication.

Addressing the Persistent Challenges in Preventing Chronic GVHD

Chronic graft-versus-host disease (cGVHD) remains one of the most consequential barriers to successful allogeneic hematopoietic stem cell transplantation (allo-HSCT), contributing substantially to late non-relapse mortality (NRM) and long-term morbidity even as transplant techniques continue to advance. Despite decades of clinical investigation, no prophylactic or therapeutic strategy has achieved consistent, durable control of cGVHD across patient populations. The challenges span disease monitoring, treatment efficacy, grading standardization, and the inherent tension between immunosuppression and graft-versus-tumor (GVT) preservation.

• Inadequate disease monitoring and grading frameworks: No reliable measures are established to monitor cGVHD activity changes suitable for use in clinical trials, and no formal response assessment guidelines exist for GVHD therapy. The current grading system offers limited clinical utility, stratifying patients only into those requiring treatment (extensive cGVHD) versus those who do not (limited cGVHD), without prognostic differentiation. A revised clinical grading system capable of classifying patients by prognosis is needed to support both clinical management and trial design.

• Partial and inconsistent efficacy of immunosuppressive regimens: Immunosuppressive agents remain the cornerstone of cGVHD management but have demonstrated only partial effectiveness. Even with standard prophylaxis — typically a calcineurin inhibitor (CNI) plus short-course methotrexate (MTX), with adjunctive mycophenolate mofetil (MMF), anti-thymocyte globulin (ATG), or anti-CD25 monoclonal antibody depending on donor type — the incidence of moderate-to-severe acute GVHD following allo-HSCT ranges from approximately 13% to 47%, and a subset of patients still progress to chronic disease. Prognosis for steroid-refractory cGVHD in particular remains poor.

• Competing risks introduced by intensified prophylaxis: More aggressive prophylactic combinations carry significant trade-offs. A 2026 analysis of ATG plus post-transplant cyclophosphamide (ATG-PTCy) demonstrated a meaningful reduction in moderate-to-severe cGVHD (11% vs. 30% with PTCy alone; HR: 2.28, p=0.001), yet two-year NRM was higher with ATG-PTCy (27% vs. 18%; p=0.04), likely attributable to increased infection risk. In AML patients specifically, overall survival favored PTCy alone (71% vs. 50% at two years, p<0.001), as the benefit of cGVHD reduction was offset by excess NRM. Similarly, a meta-analysis of ATG across six prospective randomized controlled trials found no impact on overall survival, relapse, or NRM, precluding a general recommendation for its use.

• Conflicting evidence for emerging cellular therapies: Mesenchymal stem cell (MSC) therapy has shown promise, with a meta-analysis of 15 randomized controlled trials reporting a significant reduction in cGVHD incidence (OR: 0.50; 95% CI 0.34–0.74; p=0.0005). However, results across studies remain inconsistent — bone marrow-derived MSCs (B-MSCs) and MSC infusion administered prior to HSCT have been associated with prolonged engraftment, higher relapse rates, and increased mortality, in contrast to the more favorable profile observed with umbilical cord-derived MSCs (U-MSCs) infused post-HSCT. Variations in immunosuppressive molecule expression, including HLA-G gene polymorphisms, are proposed as contributing factors to these divergent outcomes, though definitive guidance on MSC donor source and timing remains lacking.

• Long-term toxicity burden of chronic immunosuppression: Sustained immunosuppression required for cGVHD management carries its own morbidity risk, including the development of secondary malignancies. Lymphomas represent the most common immunosuppression-associated tumors, while secondary solid tumors — most frequently squamous cell carcinomas — increase in incidence over a 5–10 year delay. Oral cGVHD independently constitutes a risk factor for oral squamous cell carcinoma; in one cohort of Fanconi anemia patients post-HSCT, 42% presented with oral cGVHD manifestations, with lichenoid and hyperkeratotic lesions observed universally among affected patients.

• The GVT preservation dilemma: A fundamental unresolved challenge is calibrating immunosuppression intensity to control cGVHD severity without abrogating the graft-versus-tumor (GVT) effect, which is independently associated with improved overall survival and reduced relapse. Future therapeutic strategies must navigate this balance carefully, and factors predicting individual disease severity — which would enable risk-stratified, personalized prophylaxis — remain incompletely understood, underscoring the urgent need for further randomized studies and long-term follow-up programs.

Tregzi's Novel Treg-Cell Mechanism in the Evolving Landscape

The prevention of chronic graft-versus-host disease (cGVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) is advancing beyond calcineurin inhibitor–based regimens, with multiple mechanistically distinct approaches demonstrating clinical promise in recent literature. Emerging strategies span selective immune cell modulation, optimized cytotoxic conditioning, and novel pharmacological adjuncts, reflecting a more nuanced understanding of cGVHD pathogenesis involving aberrant donor immune activation, alloreactive T-cell infiltration, and dysregulated cytokine signaling.

• Post-Transplantation Cyclophosphamide (PTCy): PTCy has demonstrated significant reduction in cGVHD incidence compared with standard calcineurin inhibitor–based regimens (OR: 0.47, 95% CI: 0.37–0.60), with improved GVHD-free/relapse-free survival (OR: 2.29, 95% CI: 1.42–3.67). In a separate cohort of 78 allo-HSCT patients, cGVHD occurred significantly more frequently in those not receiving PTCy (p = 0.0001). Notable adverse events include cytomegalovirus reactivation (29%) and hemorrhagic cystitis (20%).

• ATG-PTCy Combination in Haploidentical Transplantation: The addition of anti-thymocyte globulin (ATG) to PTCy further reduced moderate-to-severe cGVHD rates to 11% versus 30% with PTCy alone (HR: 2.28, p = 0.001). However, this benefit was offset by increased relapse and non-relapse mortality, with overall survival remaining comparable between regimens.

• Optimised Model-Based ATG Dosing: Pharmacokinetic/pharmacodynamic modelling incorporating absolute lymphocyte count, body weight, and graft source as key covariates has enabled individualized ATG exposure. This model-based dosing strategy achieved superior CD4⁺ T-cell reconstitution, reduced viral reactivation, and decreased both cGVHD incidence and graft failure — without significantly increasing acute GVHD rates.

• Mesenchymal Stem Cells (MSCs): MSC administration significantly reduced cGVHD incidence versus controls (OR: 0.50; 95% CI: 0.34–0.74; p = 0.0005), with a dose range of 1 × 10⁶ to < 4 × 10⁶ cells/kg identified as optimal. The mechanism involves MSC-derived cytokines and exosomes that suppress Th17 cells while promoting IL-10-expressing regulatory T cells (Tregs), collectively attenuating the inflammation and tissue fibrosis characteristic of cGVHD.

• Low-Dose Interleukin-2 (IL-2) Post-Haploidentical HSCT: Early post-transplant low-dose IL-2 administration promoted in vivo expansion of NK cells and Tregs, with the 5-year cGVHD incidence significantly lower in the IL-2 group versus controls (p = 0.018), alongside superior GVHD progression-free survival (p = 0.025). Post-treatment analyses confirmed increased circulating NK cells, Treg cells, CD62L⁺ expression on Tregs and conventional T cells, and elevated plasma IFN-γ, TNF-α, IL-10, and IL-2 levels.

• Regulatory T Cells (Tregs), NK Cells, and CAR-T Cells: Cell-based immunoregulatory therapies — including polyclonal Tregs, NK cells, and CAR-T cells — are under active investigation as mechanistically targeted approaches to suppressing alloreactivity. Tregs and NK cells operate through complementary pathways to rebalance donor immune responses, and are considered a more precise alternative to broad immunosuppression.

• Sitagliptin (DPP-4 Inhibitor) as Prophylactic Adjunct: Addition of low-dose sitagliptin to standard CNI/MTX prophylaxis significantly reduced liver aGVHD incidence (3.1% vs. 18.2%; p = 0.044) and accelerated neutrophil engraftment (median 9 vs. 11 days; p < 0.001) in a 66-patient study. While reductions in cumulative grade II–IV aGVHD by day +100 (30.3% vs. 39.4%; p = 0.26) and grade III–IV aGVHD (9.1% vs. 12.1%; p = 0.70) did not reach statistical significance, the organ-specific and engraftment benefits support further evaluation.

• Two-Step Transplant Approach: This approach separates lymphoid and myeloid graft components, administering cyclophosphamide after lymphoid infusion and prior to CD34-selected stem cell infusion to optimise T-cell dosing. In 18 patients — predominantly haploidentical donors under reduced-intensity conditioning — cumulative incidences of both grade 2–4 acute GVHD and cGVHD were 17%, with a graft failure rate of 5.9%, markedly lower than the 17.5% observed with traditional one-step transplantation.

• Ruxolitinib (JAK1/2 Inhibitor) for Established cGVHD: In a retrospective study of 23 cGVHD patients, ruxolitinib achieved an overall response rate of 78.3%, with 55.6% of responders attaining complete response and 72.2% sustaining complete remission at a median follow-up of 14 months. Three-year overall survival for responders was 33.3% (95% CI: 9.2%–57.4%), with no cytomegalovirus reactivation events and predominantly mild cytopenias (34.7%), supporting its emerging role as a safe second-line therapeutic option.

PRECISION-T: Demonstrating Superior GVHD-Free Survival

The clinical evidence base for chronic GVHD prevention in allogeneic HSCT spans diverse therapeutic strategies—from pharmacological prophylaxis to cellular and gene-modified approaches—across multiple study designs and time periods. The trials summarized below reflect a spectrum of interventions evaluated in hematologic malignancy populations, with endpoints encompassing both GVHD incidence and broader transplant outcomes.

Reshaping the Chronic GVHD Prevention Landscape with Tregzi

Over the past five years, post-transplantation cyclophosphamide (PTCy)-based regimens have emerged as a central pillar in chronic GVHD (cGVHD) prevention following allogeneic hematopoietic stem cell transplantation (HCT). A 2023 Phase II study at the University of Minnesota evaluating PTCy (50 mg/kg on days +3 and +4) combined with tacrolimus and mycophenolate mofetil (MMF) in 125 pediatric and adult patients demonstrated a cumulative incidence of cGVHD requiring systemic immunosuppression of just 4% at one year — a landmark reduction compared to historical cyclosporine/methotrexate cohorts. Two-year overall survival reached 80% and GVHD-free, relapse-free survival (GRFS) 57%, without a meaningful increase in relapse risk. Complementing this, a chemotherapy-free conditioning approach combining total marrow and lymphoid irradiation (TMLI) at 2000 cGy with PTCy and tacrolimus demonstrated a moderate-to-severe cGVHD cumulative incidence of only 11.9%, with 0% non-relapse mortality and a two-year OS of 86.7% in AML patients. However, a 2022 Phase III multicenter trial enrolling 346 patients with acute leukemia or myelodysplasia found that while CD34 selection significantly reduced moderate-to-severe cGVHD (HR 0.25; P = .02), it did not translate into improved chronic GVHD/relapse-free survival (CRFS) over tacrolimus/methotrexate controls, and was associated with higher transplant-related mortality. PTCy remained competitive, showing a trend toward lower relapse (HR 0.52; P = .037) with comparable survival outcomes.

Refinements to PTCy-based platforms have also been explored through the addition of anti-thymocyte globulin (ATG). A multicenter analysis of 385 haploidentical HCT recipients compared ATG-PTCy versus PTCy alone and demonstrated that ATG significantly reduced moderate-to-severe cGVHD (11% vs. 30%; HR 2.28; P = .001), but this benefit was offset by higher non-relapse mortality (27% vs. 18%; P = .04), largely attributable to increased infectious complications. In AML patients specifically, overall survival at two years favored PTCy alone (71% vs. 50%; P < .001), underscoring that cGVHD reduction does not automatically confer a survival advantage when offset by competing risks. Meanwhile, emerging prevention strategies — including abatacept and dipeptidyl peptidase-4 inhibition — have been identified as promising but remain under evaluation in prospective trials. A 2024 review confirmed that clinical trials consistently demonstrate lower rates of severe acute and chronic GVHD with PTCy-based prophylaxis, reinforcing its growing adoption across transplant centers.

On the treatment side, the therapeutic armamentarium for established cGVHD has expanded considerably. Ruxolitinib has become the standard second-line agent following demonstration of superiority over best available therapy in the REACH3 Phase III trial for glucocorticoid-refractory cGVHD. Ibrutinib, the first FDA-approved agent for steroid-refractory cGVHD (approved August 2017), has shown modest real-world efficacy, with a two-year failure-free survival of only 9% and a median failure-free survival of 4.5 months in a 53-patient cohort. Newer approvals — belumosudil and axatilimab, the latter targeting CSF-1 receptor-dependent macrophages and monocytes implicated in cGVHD-associated fibrosis and inflammation — have expanded options in the second- and third-line settings. A comparative analysis of TKI agents (ruxolitinib, imatinib, ibrutinib) showed 12-month failure-free survival rates of 67%, 71%, and 46%, respectively, with similar overall survival across groups, and ruxolitinib demonstrating comparable efficacy to imatinib in sclerotic cGVHD. Despite this progress, no established sequencing algorithm beyond second-line therapy exists, and treatment selection continues to rely on organ involvement, prior therapy, and clinical judgment.

First Allogeneic Treg Therapy: A Milestone in GVHD Management

The recent FDA approval of Tregzi marks a significant advancement in the management of allogeneic hematopoietic stem cell transplantation (allo-HSCT), offering a novel approach to a persistent challenge. As the first allogeneic T-cell-based immunotherapy utilizing regulatory T cells (Tregs) for improving chronic graft-versus-host disease (GVHD)-free survival, Tregzi addresses a critical unmet need. Chronic GVHD remains a leading cause of morbidity and mortality for transplant recipients, and the impressive 78% chronic GVHD-free survival rate demonstrated in the PRECISION-T trial, compared to 38.4% in the control arm, represents a substantial clinical improvement for patients.

This approval not only provides a new therapeutic option but also validates the broader potential of Treg cell therapy in immune modulation. It establishes a new class of immunotherapy, signaling a strategic shift towards proactive immune tolerance induction in post-transplant care, potentially reducing reliance on prolonged conventional immunosuppression while preserving beneficial graft-versus-leukemia effects. This success could accelerate investment and development in other Treg-based indications, from autoimmune diseases to solid organ transplantation, where early studies have shown promise.

However, the journey forward for Treg therapies involves navigating several complexities. Research indicates that adoptive Treg cell therapy can, under certain conditions, inadvertently promote pathogenic Th17 cell differentiation by suppressing IL-2, potentially leading to pro-inflammatory outcomes. This highlights the importance of meticulous immune monitoring and the potential need for combination strategies, such as IL-6/STAT3 pathway blockade, to optimize therapeutic effects. Furthermore, ensuring the long-term stability, persistence, and consistent functional activity of infused allogeneic Tregs in vivo remains a key area of focus. Challenges in manufacturing scalability, cell expansion methodologies, and precise dosing strategies also persist, requiring ongoing innovation to ensure broad and equitable patient access. Despite these considerations, Tregzi's approval is a pivotal moment, paving the way for next-generation Treg therapies, including genetically modified 'Super-Tregs' or CAR-Tregs, to further enhance specificity and efficacy across a wider spectrum of immune-mediated conditions.